Announcement PDF ASX Announcement – 23 June 2023 MANAGEMENT TRANSITION Resonance Health Ltd (ASX: RHT) (Resonance Health or Company) advises that Mr Mitchell Wells has resigned as Managing Director but he will continue to serve on the Board of Directors and assist management to ensure a smooth transition. Chair of Resonance Health, Dr Martin Blake, paid tribute to the achievements of Mr. Wells: “Mitchell stepped into an Executive Director role in March 2021, and then into the role of Managing Director, following the resignation of the Company’s CEO at short notice due to personal reasons. He has led the Company as it has refashioned its internal compliance, technical and operational capabilities, to meet current and future challenges and to provide a solid foundation for future growth. With a series of exciting growth opportunities in medical imaging analysis before it, the Company can now look to the future optimistically and can be confident that it can deliver on these opportunities for patients, clinicians, pharmaceutical companies, and shareholders - all the while maintaining the high level of regulatory compliance demanded in the medical sector. I sincerely thank Mitchell for his efforts, and we look forward to his continued support of Resonance Health as a valued member of our Board.” The Board is pleased to announce the appointment of Mr Andrew Harrison as CEO of the Company, with a start date of 1 July 2023. Mr Harrison is an experienced CEO and Non-Executive Director of both publicly listed and private companies, across a range of industries, including radiology and medical artificial intelligence. He founded and was Managing Director of Capitol Health Limited (ASX: CAJ) one of Australia’s largest radiology companies. He has extensive experience in capital market transactions, technology commercialisation, local and international mergers and acquisitions, and strategic restructuring and turnaround. He has substantial international experience including in European, US, and Chinese markets. Mr Harrison also served on the Board of Enlitic LLC a world leading US based medical AI company. Dr Martin Blake said: “The Board is delighted that Andrew has agreed to take on the CEO role. Given his deep knowledge of the radiology industry, experience in artificial intelligence, and track record of growing organisations, the Board is confident that Resonance Health is in very capable hands. Andrew brings a clear capacity to identify, develop and implement sound and realistic strategies tailored for the challenges and opportunities in the medical technology sector. His extensive experience in strategic restructuring and turnaround, his engaging leadership style and his transparent, commercial, and professional approach will be key to building shareholder value and confidence.” Mr Harrison’s key employment terms are set out below. In determining Mr Harrison’s target remuneration, the Board reviewed a number of external sources and benchmarks. The Board has aimed to develop an effective remuneration framework that increases shareholder value by rewarding Mr Harrison for strong business performance. Consistent with this strategy, his remuneration Resonance Health Ltd ABN: 96 006 762 492 141 Burswood Road, Burswood, WA 6100, AUSTRALIA Postal: PO Box 71, Burswood, WA 6100, AUSTRALIA www.resonancehealth.com T + 61 8 9286 5300 info@resonancehealth.com package includes STI and LTI components that are specifically designed to ensure that Mr Harrison’s interests and those of shareholders are closely aligned. About Resonance Health Resonance Health is an Australian healthcare technology and services company. The Company’s services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high quality quantitative assessments essential in managing diseases and drug development. Resonance Health’s dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (SaMDs) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. About Andrew Harrison Mr Harrison is an experienced CEO and Non-Executive Director of both publicly listed and proprietary companies, across a range of sectors including healthcare (radiology and dental), resources, and the commercialisation of proprietary intellectual property. He has extensive experience in capital market transactions, including IPO activities, both local and international mergers and acquisitions, strategic restructuring and turnaround, and the management of distributed branch network organisations. He has held senior executive roles with Brambles Australia, been a consultant to Chubb Australasia, was Managing Director and a Non-Executive Director of ASX listed Neptune Marine Services Limited and a NonExecutive & Executive Director of Draig Resources Limited. He founded and was a Director and CEO of Capitol Health Ltd and was also a Director of Enlitic LLC. Mr Harrison holds a Bachelor of Commerce degree with honours from Curtin University Business School (WA). Key Terms of CEO’s Agreement The key terms of Mr Harrison’s employment arrangements are summarised below. - Fixed remuneration of $300,000 per annum including statutory superannuation. Short-term incentive of up to 30% of fixed remuneration based on the achievement of KPIs aligned with shareholder interests, or payable in the event of a Change of Control. Long-term incentive of up to 30% of fixed remuneration, to be agreed and issued under the Company’s ESOP. Employment may be terminated by the Company or Mr Harrison on 3 months’ notice. This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Ltd. For further information please contact: Andrew Harrison – Chief Executive Officer E: andrewh@resonancehealth.com P: +61 (0)8 9286 5300 Mitchell Wells – Managing Director E: mitchellw@resonancehealth.com P: +61 (0)8 9286 5300 Stakeholders, including clinicians, patients, and shareholders, are encouraged to register their interest at www.resonancehealth.com and to follow Resonance Health on Facebook, LinkedIn, and Twitter. Page 2